Option Care Health (OPCH) Lifted Revenue Guidance, Is It Still Undervalued?

Why Option Care Health Stock Is Back on Investors’ Radar

Option Care Health (OPCH) is drawing attention after reporting second quarter 2026 results, updating full year revenue guidance, and outlining ongoing plans for acquisitions alongside share buybacks and organic investment.

See our latest analysis for Option Care Health.

The recent Q2 2026 earnings release and updated revenue guidance appear to have shifted sentiment toward Option Care Health, with the stock posting a 1 month share price return of 9.46% and a 90 day share price return of 14.98%. This comes even though the year to date share price return is down 28.57% and the 3 year total shareholder return is down 31.01%.

If you are reassessing your healthcare exposure after Option Care Health's latest update, it could be a good moment to look at other companies shaping the sector through 41 healthcare AI stocks

Option Care Health now has a clearer earnings picture and an active capital plan, and the share price has reacted. The real tension is whether that business strength is already reflected in the price or not, which is where valuation comes in next.

Most Popular Narrative: 19.4% Undervalued

The most followed narrative currently values Option Care Health at $28.58 per share, compared with the last close of $23.03. It anchors that view in the company’s specialty infusion footprint and capital allocation plans.

Strategic capital deployment through share repurchases, targeted M&A, and internal investments positions Option Care Health to further accelerate top-line growth and diversify earnings, driving long-term adjusted EPS and earnings expansion.

Read the complete narrative.

Want to see what is sitting behind that fair value gap? The narrative leans heavily on future earnings, margin expansion and a tighter share count. Curious which mix of growth, profitability and discount rate assumptions gets to that price.

Result: Fair Value of $28.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to factor in therapy mix and reimbursement risk at Option Care Health, since shifts in these areas could quickly change earnings visibility and sentiment.

Find out about the key risks to this Option Care Health narrative.

Another View On Option Care Health’s Valuation

The popular narrative frames Option Care Health as 19.4% undervalued based on earnings and price targets. A different lens comes from the SWS DCF model, which puts fair value at $18.10 per share compared with the current $23.03. On that basis the stock screens as overvalued. Which story do you find more convincing?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and concern around Option Care Health feels familiar, that is a signal to check the numbers yourself and form your own view using the 3 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Option Care Health?

If Option Care Health has sharpened your focus on where to put fresh capital next, do not stop here. Use the Simply Wall St screener to compare other ideas fast.

• Target steadier potential returns by reviewing companies with reliable fundamentals and conservative risk profiles through the 81 resilient stocks with low risk scores.
• Hunt for businesses that might trade below their estimated worth by checking the 55 high quality undervalued stocks.
• Strengthen your watchlist with companies that pair sound balance sheets and healthier financial structures using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com